MedTrace Logo

Flow-Controlled vs. Pressure-Controlled Ventilation in CABG: Effects on Lung Aeration and Diaphragm Function

NCT07800741 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-09-02

No results posted yet for this study

Summary

Pulmonary atelectasis and loss of lung aeration are common complications following cardiac surgery with cardiopulmonary bypass (CPB) and are associated with impaired oxygenation and prolonged mechanical ventilation. Diaphragm dysfunction occurring in the perioperative period may further delay extubation and prolong intensive care unit (ICU) stay. Flow-Controlled Ventilation (FCV) is a novel ventilation modality that provides continuous, flow-based delivery of tidal breaths with a triangular flow profile, potentially offering superior dynamic compliance optimisation compared to conventional Pressure-Controlled Ventilation (PCV).

Conditions

  • Coronary Artery Disease
  • Postoperative Pulmonary Complications
  • Pulmonary Atelectasis, Postoperative
  • Diaphragm Dysfunction
  • Respiratory Insufficiency

Interventions

PROCEDURE

Flow-Controlled Ventilation

FCV delivers tidal ventilation via a continuous triangular flow waveform, maintaining constant inspiratory and expiratory flow rates throughout the entire respiratory cycle. PEEP and peak airway pressure are titrated independently, guided by dynamic respiratory system compliance. Tidal volume target is 6-8 mL/kg ideal body weight. This ventilation modality is distinct from pressure-controlled and volume-controlled modes, which generate decelerating inspiratory flow profiles and do not allow simultaneous independent titration of PEEP and peak airway pressure based on compliance.

PROCEDURE

Pressure-Controlled Ventilation (PCV)

PCV is delivered using a standard anaesthesia workstation in pressure-controlled mode. Inspiratory pressure is set to achieve a tidal volume of 6-8 mL/kg ideal body weight. PEEP is titrated using the same compliance-guided algorithm applied in the FCV arm. Unlike FCV, the inspiratory flow profile is decelerating and PEEP and peak airway pressure are not independently optimised in a compliance-guided manner within the same ventilation mode

Sponsors & Collaborators

  • Koşuyolu Kartal Heart Training and Research Hospital

    lead OTHER

Principal Investigators

  • Ebru GIRGIN DINC · Koşuyolu Kartal Heart Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2028-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07800741 on ClinicalTrials.gov